What’s New?
Gemphire Therapeutics (GEMP) is a small-cap ($14 million), clinical?stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia. I have previously highlighted the scientific and managerial errors that have hindered the clinical development of gemcabene beyond six months. Financially, this has been costly, leading to a reduction in its workforce.
In my first article, I hinted at the lack of objectivity from the management as contributing to its clinical dilemma. In engaging Ladenburg Thalmann & Co. Inc. as its strategic financial advisor, I sense some objectivity has been